Congenital disorders of glycosylation (CDG) 
Introduction

N-linked glycosylation is a widespread and essential modification of proteins in eukaryotes. Oligosaccharides are first assembled on the lipid-carrier dolichol and then transferred co-translationally to asparagine residues of nascent glycoproteins
. Loss or gain of individual N-glycosylation sites can alter the stability and function of the corresponding glycoprotein. Along this line, some forms of metachromatic leukodystrophy [3] , thrombophilia [4, 5] and ␣1-antitrypsin deficiency [6] are caused by mutations leading to the loss of N-glycosylation sites. Alternatively, the gain of a Nglycosylation site in the IFN␥ R2 protein has been shown to abolish IFN␥ response in a form of immunodeficiency [7] . By [8] [9] [10] . Considering the broad impact of glycosylation on protein functions, CDG are associated with developmental delay, malformations and multiple organ dysfunctions [11] . Although symptoms such as coagulopathies, gastrointestinal bleeding and protein-losing enteropathy are seen in specific types of CDG, hepatic and tissue fibrosis is a common feature observed in several forms of CDG. In some CDG cases, skin abnormalities such as cutis laxa [12] and ichthyosis [13] have also been described. However, the molecular mechanisms underlying most CDG symptoms are largely unclear [14] .
contrast, defects of lipid-linked oligosaccharide (LLO) biosynthesis cause generalized decreased N-glycosylation sites occupancy due to limited availability of complete LLO in the endoplasmic reticulum (ER) leading to pleiotropic changes. In addition, the structure of Nglycans on glycoproteins can be defective when glycan processing and elongation steps are altered in the secretory pathway. Both forms of N-glycosylation defects belong to the family of congenital disorders of glycosylation (CDG)
Alterations of N-glycosylation affect multiple signalling pathways by altering the stability of membrane proteins or the signalling ability of membrane receptors [15] . For example, the loss of specific N-glycan branches increases the endocytosis of the glucose transporter GLUT2 [16] and of several cytokine receptors [17] . Similarly, changes of N-glycan core fucosylation inhibits Transforming growth factor-␤ (TGF-␤) signalling, which leads to decreased production of extracellular matrix (ECM) proteins and to lung emphysema in ␤1-6 fucosyltransferase (FUT8) deficient mice [18] . Increased core fucosylation of N-glycans has also been observed in CDG cases with defects in the LLO synthesis pathway [19, 20] , whereas the cytokine TGF-␤ is a central regulator of the production of ECM proteins [21] , additional proteins, such as factors of the CCN family [22] and the matricellular protein SPARC [23] [24, 25] , ALG12 mannosyltransferase (ALG12-CDG, CDG-Ig) [26] [27] [28] and ALG6 glucosyltransferase (ALG6-CDG, CDG-Ic) [29] 
Materials and methods
Cell culture
Primary fibroblasts from three healthy control subjects and from nine CDG patients were isolated from a skin biopsy and were grown in DMEM (Invitrogen, Basel, Switzerland) 
Oligonucleotide arrays
Total RNA was isolated from fibroblast cultures and reverse transcribed as described previously [30] 
Western blot analysis
Proteins from the post-nuclear supernatants of fibroblast cells were separated by 10% SDS-PAGE and transferred to nitrocellulose membranes according to Towbin et al. [34] [30] . Genes with similar expression profiles in the different CDG were resolved by hierarchical clustering. This analysis showed that multiple genes encoding components of the extracellular matrix were highly induced in the three forms of CDG (Fig. 1) (Fig. 2A) 
Results
To appreciate the range of cellular responses linked to glycosylation disorders, we have analysed the global gene transcription profile of ALG6-CDG, DPM1-CDG and ALG12-CDG fibroblasts by oligonucleotide array hybridization
. The increased collagen production was confirmed by immunofluorescence analysis of fibroblasts performed with an antibody to collagen type-I (Fig. 2B). The induction of ECM components in CDG was also confirmed by
Western blot analysis of the proteins IGFBP5, COMP, endoglin and PSG1 (Fig. 3 
), whereas the production of ECM proteins by fibroblasts is often associated to myofibroblastic differentiation, such a phenotype was not observed in CDG fibroblasts, as assessed by the low level of the myofibroblast marker protein ␣-smooth muscle actin [38] (data not shown).
The cytokine TGF-␤ is a prominent stimulus of ECM expression [21] . To examine whether CDG fibroblasts are more sensitive to TGF-␤ than control fibroblasts, we treated CDG and control fibroblasts with the profibrotic cytokine TGF-␤. The levels of collagen production were strongly increased in all treated cells with the exception of DPM1-CDG fibroblasts (Fig. 4) [39] . Therefore, we did test whether the increased IGFBP5 expression in CDG fibroblasts could be related to the increased production of ECM components in these cells. We incubated control fibroblasts with recombinant IGFBP5 at increasing concentrations. The addition of IGFBP5 at 0.25 g/ml was sufficient to increase the level of collagen production after 2 days, whereas this effect was highest at an IGFBP5 concentration of 1.5 g/ml (Fig. 6) . This effect was similar to that obtained when stimulating fibroblasts with 10 ng/ml of TGF-␤. [15] . CDG with defects of LLO synthesis pathway leads to unoccupied N-glycosylation sites. To address the physiological processes and molecular pathways altered by deficient N-glycosylation site occupancy, a global gene transcription array study was performed in different CDG subtypes. In an earlier study, we could show that the unfolded protein response and amino acid metabolism were induced in CDG fibroblasts [30] . In this work, we have shown that pro-fibrotic genes were also induced in CDG fibroblasts. This observation fits with the observation of tissue fibrosis in some types of CDG [40] [41] [42] [43] .
Overall we showed that decreased N-glycosylation site occupancy parallels the expression of ECM genes. The unchanged TGF-␤ signalling pathway in control and patient cells pointed to a different molecular mechanism of ECM induction. The fact that it was possible to increase the collagen expression by recombinant IGFBP5 in controls showed that this protein is probably involved in the induction of ECM gene expression in CDG.
Discussion
N-linked glycosylation is required for the proper function of many glycoproteins. The stability of membrane proteins is depending on the branching of N-glycans and the degree of N-glycosylation site occupancy
The overexpression of COMP in CDG fibroblasts may be related to the interaction of this protein with some types of collagen, such as collagen type-I, which was also overexpressed in CDG fibroblasts. COMP expression has been shown to be TGF-␤ dependent in systemic sclerosis [44] , atherosclerotic lesions [45] and chronic pancreatitis [46] . Altered folding and secretion of COMP causes pseudoachondroplasia [47] , but changes of COMP expression have not been associated with pathogenic phenotypes yet.
Fig. 2 Collagen type-I levels in CDG and healthy control fibroblasts. Total collagen in fibroblasts measured by Sircol assay, shown are averages and SEM of three assays (A). Immunofluorescence staining of collagen type-I in healthy control fibroblasts (B), ALG6-CDG fibroblasts (C), DPM1-CDG fibroblasts (D) and ALG12-CDG fibroblasts (E).
Identifying the underlying molecular reasons for the up-regulation of ECM genes can provide clues for potential therapeutic targets. We first tested the TGF-␤ signalling pathway as the possible actor. Although some members of the TGF-␤ signalling pathway were among the induced genes, the whole pathway was not induced in CDG and also the sensitivity of the pathway was not altered. Therefore, a second agent, IGFBP5 that is less well characterized than TGF-␤ was investigated as a booster of ECM gene expression (Fig. 5) . Stimulation of control fibroblasts with IGFBP5 indeed showed a similar effect of collagen induction as the stimulation with TGF-␤. This observation could be extended to CDG fibroblasts (Fig. 6) . The IGFBP5 protein has previously been associated to fibrosis. IGFBP5 is over-expressed in systemic sclerosis fibroblasts and in idiopathic pulmonary fibrosis [39, 48] . Adenoviral expression of IGFBP5 in skin of mice induced fibrosis with increased dermal thickness and increased deposition of collagen and fibronectin [49] . IGFBP5 is proposed to be a central player in the initiation of fibrosis and in the response to injury [49, 50] . However, the molecular basis of [51, 52] . The IGF axis is a key regulator of cellular growth, differentiation and apoptosis processes [53] . Probably the more relevant mechanism for the ECM induction by IGFBP5 is the ability of IGFBP5 to bind to ECM components such as collagens, fibronectin and heparan sulphates [54, 55] 
IGFBP5-mediated fibrosis is not yet completely understood. Members of the family of the IGFBPs bind with high affinity to the insulin-like growth factors (IGF)-I and -II and therefore regulate the activity of the IGF-axis either positively or negatively
